Cipla Ltd.


  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
Jul 24, 2017
Prev close: 569.55
Jul 24, 2017
Market cap:
Market cap(USD):
Shares: 804.67M

Currency in INR

Company profile

Market(Ticker): BOM(500087)
Health Technology
Pharmaceuticals: Other
Full time employees: 32,374

Business summary

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. Its products portfolio include prescription drugs, animal healthcare products, bulk drugs, OTC products, agrochemicals and technology. The company offers technology services such as consulting, project appraisal, engineering, plant supply, commissioning, training, know-how transfer and quality control. Cipla was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Company background

Cipla is a major Indian generic drugmaker, competing for second place in the industry in India in terms of the size of its business. It has been doing business in 170 countries and has over 30 production bases. It is a long-established company compared with other Indian leading generic drugmakers. The predecessor of Cipla was founded by K. A. Hamied in 1935, long before India's independence in 1947. It is said that Mahatma Gandhi visited Cipla and asked Hamied to supply medicines that were desperately needed in India at the time. During World War II, Hamied crisscrossed the country to supply medicines that were in short supply due to stagnant imports.

As a trailblazer in India's pharmaceutical industry, Cipla has been busily expanding its business in Africa and other emerging economies. In particular, it is well-known for its low-cost HIV drug. In 2013, it turned a South African company it did business with into a wholly owned subsidiary.

K. A. Hamied's son Yusuf, who earned a doctorate in organic chemistry from the University of Cambridge, took over the company in 1972 and has been serving as the chairman. The founding family owns nearly 40% of the shares in the company.

In the news

Financial highlights

Mar 2017

  • Local currency
  • US Dollar
Revenue 142,298.1M
Gross profit 48,235.8M
Operating income 16,856.8M
Income before tax 12,221.7M
Net income 10,063.9M
EBITDA 25,571.4M
Diluted EPS 12.5
Dividends per share 2
Total assets 209,532M
Total liabilities 79,755M
Total equity 125,254.2M
Operating cash flow 22,368.9M

Currency in INR

Revenue 2,122.04M
Gross profit 719.32M
Operating income 251.37M
Income before tax 182.25M
Net income 150.07M
EBITDA 381.33M
Diluted EPS 0.18
Dividends per share 0.02
Total assets 3,226.79M
Total liabilities 1,228.22M
Total equity 1,928.91M
Operating cash flow 333.58M

Currency in USD

Valuation measures

Mar 2017

PER 47.30
ROA 4.78%
ROE 8.37%
Operating margin 11.84%
Profit margin 7.07%

Key executive

  • Chief Executive Officer, MD & Director: Umang Vohra
  • Global Chief Financial Officer: Kedar Upadhye
  • Secretary & Compliance Officer: Rajendra Chopra
  • Executive Vice Chairman: Samina Vaziralli
  • Head-Investor Relations: Alpesh Dalal

Share holders

  • AHMED SOPHIE(5.7%)
  • Life Insurance Corp. of India(5.6%)
  • First State Investment Management (UK) Ltd.(5.6%)
  • ICICI Prudential Asset Management Co. Ltd.(5.1%)
  • HDFC Asset Management Co. Ltd.(1.9%)
  • Norges Bank Investment Management(1.6%)
  • The Vanguard Group, Inc.(1.3%)


  • Website:
  • Address: Mumbai Central, Mumbai, 400 008, India
  • Phone: +91.22.23082891

Copyright © 2017 FactSet Research Systems Inc. All rights reserved.